Comparative Pharmacology
Head-to-head clinical analysis: COR OTICIN versus DERMABET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COR OTICIN versus DERMABET.
COR-OTICIN vs DERMABET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
COR-OTICIN is a combination product containing hydrocortisone (a corticosteroid with anti-inflammatory and immunosuppressive properties) and neomycin (an aminoglycoside antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit) and polymyxin B (a polymyxin antibiotic that disrupts bacterial cell membrane permeability).
Betamethasone dipropionate is a corticosteroid that diffuses across cell membranes and binds to glucocorticoid receptors, forming a complex that translocates to the nucleus and modulates gene transcription. It induces phospholipase A2 inhibitory proteins (lipocortins), thereby inhibiting the release of arachidonic acid and decreasing the synthesis of prostaglandins and leukotrienes. This results in anti-inflammatory, antipruritic, and vasoconstrictive effects.
1-2 drops in each affected ear twice daily for 7 days.
Apply a thin layer to affected area once or twice daily. Maximum 50 g per week.
None Documented
None Documented
Terminal half-life 4-6 hours; prolonged in renal impairment (up to 12-15 hours)
Terminal elimination half-life: 3-4 hours; prolonged in hepatic impairment
Renal (60-80% unchanged), fecal/biliary (5-10%)
Renal (60-70% as unchanged drug and metabolites), biliary/fecal (30-40%)
Category C
Category C
Topical Corticosteroid + Antibiotic
Topical Corticosteroid